Skip to main content

UPS To Support Distribution Of Approved Vaccine As Part Of Operation Warp Speed

Written by Customer Service on . Posted in Public Companies.

ATLANTA, Dec. 12, 2020 (GLOBE NEWSWIRE) —Deployments began after federal mandate to distribute therapies within 24 hours of emergency use authorization.UPS to help transport the initial Pfizer-BioNTech COVID-19 vaccine doses to support vaccinations of healthcare workers.UPS (NYSE:UPS) today announced its involvement and full support of distribution efforts for Pfizer-BioNTech’s COVID-19 vaccine as part of Operation Warp Speed. Pfizer’s and BioNTech’s vaccine, approved through a U.S. Food and Drug Administration emergency use authorization (EUA), is the first to be deployed in a months-long global race to develop safe vaccines to combat the spread of the COVID-19 virus.“Vaccine distribution is a key part of moving our world forward by delivering what matters,” says Carol Tomé, CEO of UPS. “We have dedicated and hardworking people around the world who have been trained to store, handle, transport and deliver vaccines. We’re pleased to support our healthcare partners with smart, efficient logistics for these vaccines that will protect communities and save lives.”UPS will move the Pfizer-BioNTech COVID-19 vaccine within the first days to states designated by Pfizer, Inc. based on orders received by Operation Warp Speed and CDC officials.“This is the moment of truth we’ve been waiting for at UPS,” says Wes Wheeler, president of UPS Healthcare. “We have spent months strategizing with Operation Warp Speed officials and our healthcare customers on efficient vaccine logistics, and the time has arrived to put the plan into action.”Pfizer-BioNTech COVID-19 vaccines will originate from storage sites in Michigan and Wisconsin. The vaccines will be transported to UPS Worldport facilities in Louisville, where they will be expedited Next Day Air to select destinations, including hospitals, clinics and other medical facilities, to inoculate healthcare workers.  “This is undoubtedly a historic feat not only for vaccine development but also expedient deployment,” says Mike McDermott, President, Pfizer Global Supply. “We know that agile, world-class logistics is critical to get our products where they are needed, and we’re happy to partner with UPS in this historic effort to save lives and create healthier communities right now and well into the future.”About UPS HealthcareUPS Healthcare operates 128 facilities in 32 countries which are regulated under Good Manufacturing Practices (GMP). UPS Healthcare services include: inventory management, temperature-controlled packaging and shipping, storage and fulfillment of medical devices, labs and clinical trial logistics. UPS Healthcare’s global infrastructure, its newest UPS Premier visibility service, its track and trace technology, and its global quality system are well-suited to meet today’s complex logistics demands for the pharmaceutical, medical device and laboratory diagnostic industries. Visit ups.com/healthcare.UPS Media Relations
404-828-7123
pr@ups.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.